Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression

Table 1 Table 1

Status	N (%)
Treatment Completed per protocol	21 (62%)
Disease Progression	3 (9%)
Early termination due to adverse event*	5 (15%)
Early termination due to patient withdrawal**	2 (6%)
Early termination – counts did not recover within time frame to begin cycle 4	1 (3%)
Treatment ongoing	2 (6%)

*1 pt with grade (gr) 4 thrombocytopenia and gr 3 infection; 1 pt with gr 3 left hemiparesis; 1 pt with gr 3 confusion unrelated to treatment; 1 pt with prior hepatitis B and cirrohosis had gr 3 encephalopathy and pulmonary infiltrates; 1 pt with gr 4 neutropenia and gr4 thrombocytopenia.
**1 CR 2 yrs post treatment.

ISSN: 1750-9378